210 related articles for article (PubMed ID: 36309225)
1. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Disease Alters Myocardial Tissue Levels of Epoxyeicosatrienoic Acids and Key Proteins Involved in Their Biosynthesis and Degradation.
Aliwarga T; Dinh JC; Heyward S; Prasad B; Gharib SA; Lemaitre RN; Sotoodehnia N; Totah RA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293289
[TBL] [Abstract][Full Text] [Related]
3. Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy.
Maayah ZH; McGinn E; Al Batran R; Gopal K; Ussher JR; El-Kadi AOS
J Cardiovasc Pharmacol; 2019 Sep; 74(3):235-245. PubMed ID: 31306370
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
Deng Y; Theken KN; Lee CR
J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972
[TBL] [Abstract][Full Text] [Related]
5. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
6. Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Dalle Vedove F; Fava C; Jiang H; Zanconato G; Quilley J; Brunelli M; Guglielmi V; Vattemi G; Minuz P
J Hypertens; 2016 Jul; 34(7):1364-70. PubMed ID: 27115337
[TBL] [Abstract][Full Text] [Related]
7. The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.
Maayah ZH; Abdelhamid G; Elshenawy OH; El-Sherbeni AA; Althurwi HN; McGinn E; Dawood D; Alammari AH; El-Kadi AOS
Cardiovasc Toxicol; 2018 Jun; 18(3):268-283. PubMed ID: 29196978
[TBL] [Abstract][Full Text] [Related]
8. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
9. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
10. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
11. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.
Nayeem MA; Hanif A; Geldenhuys WJ; Agba S
Pharmacol Ther; 2022 Dec; 240():108213. PubMed ID: 35597366
[TBL] [Abstract][Full Text] [Related]
13. Arachidonic acid cytochrome P450 epoxygenase pathway.
Spector AA
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S52-6. PubMed ID: 18952572
[TBL] [Abstract][Full Text] [Related]
14. The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.
Xu X; Li R; Chen G; Hoopes SL; Zeldin DC; Wang DW
Adv Nutr; 2016 Nov; 7(6):1122-1128. PubMed ID: 28140329
[TBL] [Abstract][Full Text] [Related]
15. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
16. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
17. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
18. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
19. Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases.
Duflot T; Roche C; Lamoureux F; Guerrot D; Bellien J
Expert Opin Drug Discov; 2014 Mar; 9(3):229-43. PubMed ID: 24490654
[TBL] [Abstract][Full Text] [Related]
20. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation.
Fleming I
Trends Pharmacol Sci; 2007 Sep; 28(9):448-52. PubMed ID: 17764757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
